What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.80%Below 5Y avg (1.88%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
118.0%High
Payback Period
59.0 yr
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.14BCNY
1.80B · vs all stocks (USD)
Updated Aug 19, 2026
Trailing P/E
97.81x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Revenue (TTM)
9.98BCNY
1.48B · vs all stocks (USD)
Updated Aug 19, 2026
Profit Margin
1.30%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Beta
0.7000x
vs all stocks
Updated Aug 19, 2026
52-Week Change
19.80%
vs all stocks
Updated Aug 19, 2026
Market Capitalization
12.14BCNY
1.80B · vs all stocks (USD)
Updated Aug 19, 2026
Enterprise Value
15.03BCNY
2.23B · vs all stocks (USD)
Updated Aug 19, 2026
Trailing P/E
97.81x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Forward P/E
31.36x
vs Diagnostics & Research peers
Updated Aug 19, 2026
PEG Ratio
-0.2408x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Price to Sales (TTM)
1.29x
vs Diagnostics & Research peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 1.22×.Updated Aug 19, 2026
Price to Book (MRQ)
1.92x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to Revenue
1.51x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Enterprise to EBITDA
16.95x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 18.82×.Updated Aug 19, 2026
Gross Margin
29.47%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Profit Margin
1.30%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Margin
8.70%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Assets (TTM)
2.68%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Return on Equity (TTM)
2.82%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Revenue (TTM)
9.98BCNY
1.48B · vs all stocks (USD)
Updated Aug 19, 2026
Revenue per Share (TTM)
16.33CNYUpdated Aug 19, 2026
Quarterly Revenue Growth
-5.00%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Gross Profit (TTM)
2.87BCNY
426.75M · vs all stocks (USD)
Updated Aug 19, 2026
EBITDA (TTM)
798.69MCNY
118.62M · vs all stocks (USD)
Updated Aug 19, 2026
Net Income (TTM)
129.43MCNY
19.22M · vs all stocks (USD)
Updated Aug 19, 2026
Quarterly Earnings Growth (YoY)
-5.00%
vs Diagnostics & Research peers
Updated Aug 19, 2026
Operating Cash Flow (TTM)
2.03BCNY
302.06M · vs all stocks (USD)
Updated Aug 19, 2026
Levered Free Cash Flow (TTM)
1.65BCNY
245.65M · vs all stocks (USD)
Updated Aug 19, 2026
Trailing Annual Dividend Rate
0.3500CNYUpdated Aug 19, 2026
Trailing Annual Dividend Yield
1.80%
vs all stocks
Updated Aug 19, 2026
5-Year Average Dividend Yield
1.88%
vs all stocks
Updated Aug 19, 2026
Payout Ratio
118.04%
vs Diagnostics & Research peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 166.67%.Updated Aug 19, 2026
Minority Interest (Equity)
2.16BCNYFY2025 · Dec 31, 2025
Revenue
10.10BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
7.22BCNYFY2025 · Dec 31, 2025
Gross Profit
2.87BCNYFY2025 · Dec 31, 2025
Operating Income
741.48MCNY
110.13M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
256.19MCNYFY2025 · Dec 31, 2025
Income Tax Expense
110.58MCNYFY2025 · Dec 31, 2025
Net Income
145.61MCNYFY2025 · Dec 31, 2025
EBIT
417.65MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
1.20BCNYFY2025 · Dec 31, 2025
Research & Development
254.54MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
649.53MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
67.20MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
24.34MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
161.46MCNYFY2025 · Dec 31, 2025
EPS (Basic)
0.0721CNYFY2025 · Dec 31, 2025
EPS (Diluted)
0.0721CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
610.99MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
610.99MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
145.61MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
-101.55MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
1.69BCNYFY2025 · Dec 31, 2025
Free Cash Flow
1.43BCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
2.10BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
145.61MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
283.39MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
1.28BCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-16.28MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-256.99MCNYFY2025 · Dec 31, 2025
Net Acquisitions
627.75KCNYFY2025 · Dec 31, 2025
Purchase of Investments
-654.40MCNYFY2025 · Dec 31, 2025
Sale of Investments
585.20MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-325.57MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.46BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-2.27BCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-255.80MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-196.23MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-1.26BCNYFY2025 · Dec 31, 2025
Shares Outstanding
624.98MSharesUpdated Aug 19, 2026
Float Shares
426.91MSharesUpdated Aug 19, 2026
% Held by Insiders
30.06%
vs all stocks
Updated Aug 19, 2026
% Held by Institutions
5.26%
vs all stocks
Updated Aug 19, 2026
Total Cash (MRQ)
2.13BCNY
316.34M · vs all stocks (USD)
Updated Aug 19, 2026
Total Cash per Share (MRQ)
3.48CNYUpdated Aug 19, 2026
Total Debt (MRQ)
2.47BCNY
367.58M · vs all stocks (USD)
Updated Aug 19, 2026
Total Debt to Equity (MRQ)
0.2857x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Current Ratio (MRQ)
2.73x
vs Diagnostics & Research peers
Updated Aug 19, 2026
Book Value per Share (MRQ)
10.68CNYUpdated Aug 19, 2026
Total Assets
14.42BCNY
2.14B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
10.86BCNYFY2025 · Dec 31, 2025
Total Liabilities
5.82BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
3.56BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.73BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
4.09BCNYFY2025 · Dec 31, 2025
Cash
2.10BCNYFY2025 · Dec 31, 2025
Cash Equivalents
7.36MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
2.11BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
444.45MCNYFY2025 · Dec 31, 2025
Accounts Receivable
5.94BCNYFY2025 · Dec 31, 2025
Inventory
1.55BCNYFY2025 · Dec 31, 2025
Accounts Payable
1.65BCNYFY2025 · Dec 31, 2025
Short-term Debt
1.51BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
30.73MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.15BCNYFY2025 · Dec 31, 2025
Common Stock (Book)
624.98MCNYFY2025 · Dec 31, 2025
Retained Earnings
3.89BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
8.60BCNY
1.28B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
199.57MCNYFY2025 · Dec 31, 2025
52-Week Low
14.48CNYUpdated Aug 19, 2026
52-Week High
33.30CNYUpdated Aug 19, 2026
52-Week Change
19.80%
vs all stocks
Updated Aug 19, 2026
Beta
0.7000x
vs all stocks
Updated Aug 19, 2026
50-Day MA
18.78CNYUpdated Aug 19, 2026
200-Day MA
19.36CNYUpdated Aug 19, 2026
Avg 10-Day Volume
38.07MSharesUpdated Aug 19, 2026
Avg 30-Day Volume
39.55MSharesUpdated Aug 19, 2026
Diluted EPS (TTM)
0.2100CNYUpdated Aug 19, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.